Key Highlights

  • Vitasora Health (ASX:VHL) reported that poorly controlled diabetes among patients in its chronic care management program at one FQHC fell to 6.7% at about 12 months.
  • Blood pressure control rose to 82.9% at about 12 months, from 79.6% at about six months, against a US national average of 67.4%.
  • The company had 42 active Care Coordinators at late October 2026 and targets about 115 by late Q1 2027.
  • Monthly billable care minutes rose about 50% to 262,104 in October, and the company continues to target cash-flow breakeven during H1 2027.

Vitasora Health Limited (ASX:VHL) announced on 9 November 2026 that patients in its chronic care management program, delivered with a US Federally Qualified Health Center, showed further improvement after about 12 months of care. The company also provided operating figures showing growth in care delivery and Care Coordinator numbers, which it presented as evidence for its connected care services.

The Clinical Results and Their Limits

The poorly controlled diabetes rate fell from 13.1% at about six months to 6.7% at about 12 months, against a national benchmark of 28.1%. Blood pressure control rose from 79.6% to 82.9%, and depression screening and follow-up improved from 70.3% to 79.5%. The company says CCM patients were ahead of national benchmarks on all 11 reported quality measures at the second report.

The data are observational and come from a single health center. The six-month figures are not pre-enrolment baselines, the same patients may not have been measured in each period, and the national comparison uses historical averages rather than a matched control group. The company itself notes these results cannot prove that the program alone produced the improvement.

Growth in Care Delivery and Staffing

Care Coordinator daily utilisation rose from about 65% to more than 95%, and monthly billable care minutes grew about 50%, from 175,324 in September to 262,104 in October. The company says this growth came from its existing customers before enrolments for new clients began. The October minute figures are management estimates pending final reconciliation.

Vitasora had a net increase of 20 Care Coordinators since 1 July, to 42 at the end of October. It is targeting 48 or more during November and about 115 by late Q1 2027. Management estimates that each fully productive Care Coordinator can generate about US$595 in daily Revenue under current assumptions, but this is described as a measure of capacity rather than a forecast.

Connected Care Portfolio and Financial Pressures

Separate remote patient monitoring results from a US primary care practice showed an average 8.5 mmHg reduction in systolic blood pressure between July and September 2026. The company’s figures were observational, with no matched comparison group.

The company has not yet reached cash-flow breakeven, and its revenue depends on eligible patient enrolment, reimbursement, billing eligibility and collections. The announcement notes that recruitment, utilisation and payer mix could materially affect actual results, and that breakeven timing is not guaranteed.

Final Word

Vitasora is presenting improved clinical outcomes and a rapidly expanding clinical workforce as the basis for its next phase of growth. The clinical findings are encouraging but limited to one partner, and the financial case depends on converting care minutes into collected revenue at scale. Progress on Care Coordinator recruitment, enrolment and reimbursement over the coming quarters will show whether the model can expand as planned.